454 Sequencing at the Forefront of Bone Marrow and Stem Cell Therapy Research
News Jun 30, 2008
The Blood Centre Linz, Austria has purchased a Genome Sequencer FLX System from Roche, for use in research on rejection reactions in Bone Marrow and Stem Cell transplantation. Using conventional Sanger sequencing it can take weeks to analyze large DNA regions.
The Genome Sequencer FLX System can achieve this task within hours, improving efficiency and reducing costs. The ultimate goal of the research undertaken with the Genome Sequencer System is to create a significant reduction in the high rate of rejection reactions in transplantation.
Typically, the odds of finding a suitable stem cell donor is 1 in 500,000. Every year in the German speaking countries, approximately 12,000 people require urgent transplantations. The success of these transplantations is largely dependent on an exact tissue matching based upon HLA typing.
With the Genome Sequencer from Roche Diagnostics, the researchers at the Blood Centre Linz will concentrate on making the HLA typing application significantly quicker and more efficient in order to ensure a significant decrease in graft rejection by a better matching recipients to donors.